ABNL-MARRO
The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes.
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1/2
- Enrollment
- 105 patients (estimated)
- Sponsors
- Vanderbilt-Ingram Cancer Center
- Collaborators
- Incyte Corporation, Theradex, Taiho Oncology, Inc.
- Tags
- Chemotherapy
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1799
- NCT Identifier
- NCT04061421
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.